U.S. Markets open in 7 hrs 36 mins

PDL BioPharma Reports 2019 Third Quarter Financial Results

Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets

Conference call at 4:30 p.m. Eastern time today

INCLINE VILLAGE, Nev., Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) reports financial results for the three and nine months ended September 30, 2019:

Third Quarter Financial Highlights

  • Total revenues were $44.2 million, including $20.3 million in product revenue and $23.9 million in revenue from royalty rights - change in fair value.
  • LENSAR revenues were $8.1 million, up 22% over the prior-year period.
  • U.S. market share for branded Tekturna and authorized generic of Tekturna remained steady at approximately 73%.
  • Net cash royalties from all royalty rights were $25.6 million, up from $19.1 million in the prior-year period.
  • GAAP net loss was $17.8 million. Non-GAAP net income was $10.4 million. A reconciliation of GAAP to non-GAAP financial results can be found in Table 3 at the end of this news release.
  • Completed $100 million share repurchase program by repurchasing 1.3 million shares of common stock in the open market for $4.1 million.

"Third quarter revenues exceeded $44 million driven by continued growth from the LENSAR Laser System and strong contributions from our royalty assets, both of which are tracking ahead of our previous guidance range," said Dominique Monnet, president and CEO of PDL. "LENSAR's quarterly revenues reached a record $8 million, up 22% over the prior-year period and up 27% year-to-date. Through PDL-funded R&D investments, LENSAR has continued to advance its best-in-class technology for the treatment of cataracts and the management of astigmatism. LENSAR's technology benefits have been increasingly recognized by ophthalmic surgeons, as indicated by steady and robust year-over-year procedure volume growth since the product was launched in mid-2012. Procedure volume for the first nine months of 2019 is on pace to continue this trend. 

"We are also pleased with progress at Evofem Biosciences, which is on track to resubmit the Amphora® NDA in the fourth quarter," he added. "Given this timeframe, we anticipate Amphora's commercial launch for the prevention of pregnancy in 2020, subject to FDA approval. We believe our strategic investment in Evofem allows our shareholders to benefit from the significant near-term and longer-term commercial potential of Amphora. It may also present a strategic position for PDL's potential expansion into the underserved women's health market.

"We completed our $100 million share buy-back program during the third quarter, which represents the Company's largest single investment year-to-date. We are also continuing our efforts to reduce our operating expenses, with general and administrative expenses (G&A) down 16% year-to-date."

Revenue Highlights

  • Total third quarter revenues were $44.2 million and included $20.3 million in product revenue and $23.9 million in revenue from royalty rights - change in fair value.
  • Total revenues for the first nine months of 2019 were $60.6 million and included $64.9 million in product revenue and negative $4.3 million in revenue from royalty rights – change in fair value.

Operating Expense Highlights

  • Operating expenses for the third quarter of 2019 were $34.7 million, a $3.6 million increase from the third quarter of 2018. The increase was primarily due to a $3.6 million increase in research and development (R&D) expenses associated with product development and patent licensing for LENSAR, and a $3.1 million, or 26%, increase in cost of product revenue, $2.4 million of which related to a termination provision in a Noden supply agreement amended in June 2019 involving end of contract fees, most of which were incurred in the third quarter of 2019. These increases were partially offset by a $1.1 million, or 8%, decline in G&A expenses, primarily due to lower professional fees, and a $1.8 million, or 51%, decline in sales and marketing expenses reflecting savings from the change in the Company's marketing strategy for the Noden Products.
  • Operating expenses for the first nine months of 2019 were $90.6 million, a $146.5 million decrease from the prior-year period. The decrease was primarily a result of the net impact of: the $152.3 million impairment of the Noden Products intangible assets in the second quarter of 2018 and related reductions to the Noden Products contingent liability and amortization expense associated with those intangible assets which, in aggregate, accounted for $139.1 million of the decrease; a $6.4 million, or 16%, decline in G&A expenses primarily due to lower professional and asset management fees; and a $7.9 million, or 55%, decline in sales and marketing expenses reflecting savings from the change in the Company's marketing strategy for the Noden Products. These decreases were partially offset by an increase in R&D expenses of $3.9 million associated with product development and patent licensing for LENSAR.

Other Financial Highlights

  • On a GAAP basis, the net loss attributable to PDL's shareholders for the third quarter of 2019 was $17.8 million, or $0.16 per share, compared with GAAP net income attributable to PDL's shareholders of $25.6 million, or $0.18 per share on a diluted basis, for the prior-year period. Noteworthy items reflected in the third quarter net loss include pre-tax charges of $3.9 million for the convertible debt exchange, a $3.6 million increase to R&D expense, primarily the result of the acquisition of LENSAR intellectual property, a $2.4 million manufacturing charge for our Noden products and a $27.4 million loss due to the decrease in fair value of our investment in Evofem, partially offset by a $3.5 million gain recognized for the sale of intangible assets. Non-GAAP net income attributable to PDL's shareholders was $10.4 million for the third quarter of 2019, compared with non-GAAP net income of $13.1 million for the third quarter of 2018.
  • The GAAP net loss attributable to PDL's shareholders for the first nine months of 2019 was $15.5 million, or $0.13 per share, compared with a GAAP net loss attributable to PDL's shareholders of $85.1 million or $0.58 per share, for the prior-year period. Non-GAAP net income attributable to PDL's shareholders was $34.9 million for the first nine months of 2019, compared with non-GAAP net income of $44.2 million for the prior-year period.
  • PDL had cash and cash equivalents of $294.3 million as of September 30, 2019, compared with cash and cash equivalents of $394.6 million as of December 31, 2018.
  • The $100.3 million reduction in cash and cash equivalents during the first nine months of 2019 was primarily the result of common stock repurchases of $75.9 million, the Company's investment in Evofem Biosciences of $60.0 million and costs incurred in the exchange of convertible debt of $11.1 million, which extended the maturity date of $86.1 million of our notes to December 2024, and net cash used in operations of $13.3 million. This was partially offset by the proceeds from royalty rights of $58.1 million and cash proceeds from the sale of intangible assets of $5.0 million.

Stock Repurchase Programs

  • In November 2018 PDL began repurchasing shares of its common stock in the open market pursuant to the
  • $100.0 million share repurchase program authorized by the Company's board of directors in September 2018.
  • During the third quarter of 2019, the Company completed the stock repurchase program by repurchasing 1.3 million shares for an aggregate purchase price of $4.1 million.
  • Since initiating its first stock repurchase program in March 2017, the Company has repurchased 53.1 million shares for $155.0 million, at an average cost of $2.92 per share.
  • As of October 31, 2019, the Company had approximately 114.2 million shares of common stock outstanding.

Financial Guidance

  • PDL is affirming 2019 financial guidance for Noden product revenue, which is expected to be in the range of $50 million to $55 million.
  • PDL now expects 2019 LENSAR product revenue to exceed $29 million and 2019 cash royalties to exceed $65 million. This compares with previous guidance for LENSAR product revenue, which was expected to be in the range of $27 million to $29 million, and cash royalties expected to be in the range of $60 million to $65 million.

Conference Call and Webcast

PDL will hold a conference call to discuss financial results and provide a business update at 4:30 p.m. Eastern time today. Slides to accompany the conference call will be available in the Investor Relations section of www.pdl.com.

To access the live conference call via phone, please dial 844-535-4071 from the U.S. and Canada or 706-679-2458 internationally. The conference ID is 3195828. A telephone replay will be available beginning approximately one hour after the call through one week following the call, and can be accessed by dialing 855-859-2056 from the U.S. and Canada or 404-537-3406 internationally. The replay passcode is 3195828.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of www.pdl.com and select "Events & Presentations."

About PDL BioPharma, Inc.

PDL's mission is to improve the lives of patients and create value for our shareholders and our people by applying our capital and expertise for the successful development and commercialization of innovative therapeutics by our partner companies. We deliver on our mission by entering into strategic transactions involving innovative late clinical-stage or early commercial-stage therapeutics with attractive revenue growth potential. For more information please visit www.pdl.com

NOTE:  PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein. Noden, Noden Pharma, Tekturna, Tekturna HCT, Rasilez and Rasilez HCT and associated logos are trademarks or registered trademarks of, and are proprietary to, Noden Pharma DAC, which reserves all right therein. LENSAR and associated logos are trademarks or registered trademarks of, and are proprietary to, LENSAR, Inc., which reserves all rights therein.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2019 and subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

 

TABLE 1

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA

(In thousands, except per share amounts)




Three Months Ended
September 30,


Nine Months Ended
September 30,



2019


2018


2019


2018

Revenues









Product revenue, net


$

20,345



$

24,387



$

64,868



$

79,472


Royalty rights - change in fair value


23,865



42,184



(4,277)



66,117


Royalties from Queen et al. patents




533



9



4,534


Interest revenue




754





2,254


License and other


(45)



40



(48)



614


Total revenues


44,165



67,898



60,552



152,991











Operating Expenses









Cost of product revenue, (excluding intangible amortization and impairment)


15,033



11,926



40,191



37,016


Amortization of intangible assets


1,575



1,577



4,745



14,254


General and administrative


12,092



13,211



33,037



39,401


Sales and marketing


1,712



3,469



6,515



14,367


Research and development


4,310



672



6,065



2,149


Impairment of intangible assets








152,330


Change in fair value of contingent consideration




302





(22,433)


Total operating expenses


34,722



31,157



90,553



237,084


Operating income (loss)


9,443



36,741



(30,001)



(84,093)











Non-operating (expense) income, net









Interest and other income, net


1,460



1,581



4,984



4,871


Interest expense


(3,011)



(2,866)



(8,950)



(9,262)


Equity affiliate - change in fair value


(27,378)





18,109




Gain on sale of intangible assets


3,476





3,476




Loss on exchange of convertible notes


(3,900)





(3,900)




Total non-operating (expense) income, net


(29,353)



(1,285)



13,719



(4,391)











(Loss) income before income taxes


(19,910)



35,456



(16,282)



(88,484)


Income tax (benefit) expense


(1,944)



9,900



(419)



(3,346)


Net (loss) income



(17,966)




25,556




(15,863)




(85,138)


Less: net loss attributable to noncontrolling interests


(182)





(340)




Net (loss) income attributable to PDL's shareholders


$

(17,784)



$

25,556



$

(15,523)



$

(85,138)











Net (loss) income per share









Basic


$

(0.16)



$

0.18



$

(0.13)



$

(0.58)


Diluted


$

(0.16)



$

0.18



$

(0.13)



$

(0.58)











Shares used to compute income per basic share


112,986



143,171



119,966



147,159


Shares used to compute income per diluted share


112,986



144,224



119,966



147,159


 

TABLE 2

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

(Unaudited)

(In thousands)




September 30,


December 31,



2019


2018

Cash and cash equivalents


$

294,270



$

394,590


Notes receivable


$

64,008



$

63,813


Royalty rights - at fair value


$

313,943



$

376,510


Investment in equity affiliate


$

67,200



$


Total assets


$

865,145



$

963,736


Total convertible notes payable


$

132,484



$

124,644


Total stockholders' equity


$

637,434



$

729,779


 

TABLE 3

PDL BIOPHARMA, INC.

GAAP to NON-GAAP RECONCILIATION:

NET (LOSS) INCOME

(Unaudited)

(In thousands)


A reconciliation between net (loss) income on a GAAP basis and on a non-GAAP basis is as follows:












Three Months Ended


Nine Months Ended



September 30,


September 30,



2019


2018


2019


2018

GAAP net (loss) income attributed to PDL's stockholders as reported


$

(17,784)



$

25,556



$

(15,523)



$

(85,138)


Adjustments to Non-GAAP net income (as detailed below)


28,157



(12,429)



50,391



129,354


Non-GAAP net income attributed to PDL's stockholders


$

10,373



$

13,127



$

34,868



$

44,216











An itemized reconciliation between net (loss) income on a GAAP basis and on a non-GAAP basis is as follows:












Three Months Ended


Nine Months Ended



September 30,


September 30,



2019


2018


2019


2018

GAAP net (loss) income attributed to PDL's stockholders, as reported


$

(17,784)



$

25,556



$

(15,523)



$

(85,138)


Adjustments:









Mark-to-market adjustment to fair value - royalty assets


1,699



(23,128)



62,567



(9,068)


Mark-to-market adjustment to equity affiliate - common stock


21,333





(16,574)




Non-cash interest revenues




(79)





(229)


Non-cash stock-based compensation expense


2,059



2,596



5,403



4,814


Non-cash debt offering costs


1,900



1,834



5,776



5,745


Non-cash depreciation and amortization expense


646



1,033



2,295



3,061


Mark-to-market adjustment on warrants held


6,090



(40)



(1,487)



(114)


Impairment of intangible assets








152,330


Non-cash amortization of intangible assets


1,575



1,577



4,745



14,254


Mark-to-market adjustment of contingent consideration




302





(22,433)


Income tax effect related to above items


(7,145)



3,476



(12,334)



(19,006)


Total adjustments


28,157



(12,429)



50,391



129,354


Non-GAAP net income


$

10,373



$

13,127



$

34,868



$

44,216


Use of Non-GAAP Financial Measures

We supplement our consolidated financial statements presented on a GAAP basis by providing an additional measure which may be considered a "non-GAAP" financial measure under applicable rules of the Securities and Exchange Commission. We believe that the disclosure of this non-GAAP financial measure provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net income, and is not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.

"Non-GAAP net income" is not based on any standardized methodology prescribed by GAAP and represents GAAP net income adjusted to exclude (1) mark-to-market adjustments related to the fair value election for our investments in royalty rights presented in our earnings, which include the fair value re-measurement of future discounted cash flows for each of the royalty rights assets we have acquired, (2) market-to-mark adjustment to our equity affiliate, (3) non-cash interest revenue from notes receivable (4) non-cash stock-based compensation expense, (5) non-cash interest expense related to PDL debt offering costs, (6) mark-to-market adjustments related to warrants held, (7) non-cash amortization of intangible assets, (8) mark-to-market adjustment related to acquisition-related contingent consideration, (9) non-cash depreciation and amortization expense and (10) the related tax effect of all reconciling items within our reconciliation. Non-GAAP financial measures used by PDL may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-reports-2019-third-quarter-financial-results-300953207.html